Travoprost (CAS 157283-68-6) Suppliers and Product Information

Travoprost is a selective FP prostaglandin receptor agonist used to treat glaucoma. It is supplied as a sterile 0.004% ophthalmic solution in 2.5 or 5.0 mL containers. Travoprost is the isopropyl ester of (±)-fluprostenol, a prostaglandin derivative belonging to the PGF2α ***og class. It is used for controlling the progression of open-angle glaucoma and ocular hypertension by reducing intraocular pressure.

Chemical Properties: - Appearance: Colorless oil - Optical Rotation: [α]D20 = 14.6° (c = 1.0 in methylene chloride) - Boiling Point: 584.8±50.0 °C (predicted) - Density: 1.245±0.06 g/cm3 (predicted) - Flash Point: 17°C - Storage: Store in freezer under -20°C, light sensitive - Solubility: Sparingly soluble in dichloromethane, chloroform, and methanol

Frequently Asked Questions about Travoprost

Q: What is Travoprost used for? A: Travoprost is primarily used for treating elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. It helps control the progression of these conditions by reducing intraocular pressure.

Q: How does Travoprost work? A: Travoprost is a FP prostaglandin receptor agonist. It stimulates intracellular Ca2 mobilization and exhibits submicromolar affinity for DP, EP, IP, and TP receptors. This mechanism helps to reduce intraocular pressure in the eye.

Q: What is the typical formulation of Travoprost? A: Travoprost is typically supplied as a sterile 0.004% ophthalmic solution in 2.5 or 5.0 mL containers, marketed under brand names such as Travatan.

Q: Are there any side effects associated with Travoprost? A: While the search results don't provide specific information on side effects, it's mentioned that cautions and side effects are similar to other prostaglandin ***ogs used for glaucoma treatment. Common side effects may include conjunctival hyperemia (eye redness), but it's generally considered safe and well-tolerated.

Q: How is Travoprost administered? A: Travoprost is administered topically as an ophthalmic solution. The typical dosage is 1 to 4 μg daily, which has been shown to reduce intraocular pressure by about 30% at 4 hours post-administration in clinical studies.